StonvexLoading…
StonvexStonvexStonvexCore line items from RNA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q1 2025 2025-03-31 |
|---|---|---|
Revenue | $19.64M | $1.57M |
Operating Income | $-17.28M | $-7.45M |
Net Income | $-16.63M | $-7.45M |
EPS (Diluted) | $-0.97 | $-0.44 |
Total Assets | $292.36M | Not available |
Total Liabilities | $58.26M | Not available |
Cash & Equivalents | $267.85M | $0.00 |
Free Cash Flow OCF − CapEx | $-33.24M | $-11.10M |
Shares Outstanding | 17.11M | 17.11M |